Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Oral heparin (Emisphere).

A Dunn1

  • 1Mount Sinai School of Medicine, Department of Medicine, New York, NY 10029, USA. andrew.dunn@mssm.edu

Idrugs : the Investigational Drugs Journal
|August 5, 2005
PubMed
Summary
This summary is machine-generated.

Emisphere is developing an oral heparin formulation using P-414 for deep vein thrombosis (DVT) prevention. Phase III trials demonstrated its safety and efficacy, comparable to injectable heparin, for post-hip replacement surgery patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

In sickness and health? Examining the co-occurrence and concordance of healthy lifestyle behaviours among spouses in Namibia.

Public health·2024
Same author

Return to sport and beyond following intramuscular tendon hamstring injury: A case report of an English Premier League football player.

Physical therapy in sport : official journal of the Association of Chartered Physiotherapists in Sports Medicine·2022
Same author

Assigning a structural motif using spontaneous molecular dipole orientation in thin films.

Physical chemistry chemical physics : PCCP·2018
Same author

Blood immune transcriptome analysis of artificially fed dairy calves and naturally suckled beef calves from birth to 7 days of age.

Scientific reports·2018
Same author

Maternal immune activation in mid-late gestation alters amphetamine sensitivity and object recognition, but not other schizophrenia-related behaviours in adult rats.

Behavioural brain research·2018
Same author

Corrigendum to "Prediction of antidepressant response in both 2.25 × threshold RUL and fixed high dose RUL ECT" [J. Affect. Disord. 112 (1-3) (2009) 85-91].

Journal of affective disorders·2018
Same journal

Filibuvir, a non-nucleoside NS5B polymerase inhibitor for the potential oral treatment of chronic HCV infection.

IDrugs : the investigational drugs journal·2010
Same journal

Remimazolam, a short-acting GABA(A) receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures.

IDrugs : the investigational drugs journal·2010
Same journal

LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome.

IDrugs : the investigational drugs journal·2010
Same journal

Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis.

IDrugs : the investigational drugs journal·2010
Same journal

Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety.

IDrugs : the investigational drugs journal·2010
Same journal

Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.

IDrugs : the investigational drugs journal·2010
See all related articles

Area of Science:

  • Pharmacology
  • Drug Delivery Systems

Background:

  • Deep vein thrombosis (DVT) is a significant post-operative risk.
  • Current treatments primarily involve injectable anticoagulants.
  • Oral heparin formulations offer a potential alternative to injections.

Purpose of the Study:

  • To evaluate the safety and efficacy of an oral heparin formulation for DVT prevention.
  • To compare oral heparin with injectable enoxaparin sodium in post-hip replacement surgery patients.
  • To assess the tolerability and comparability of oral heparin to subcutaneous heparin.

Main Methods:

  • Phase I, II, and III clinical trials were conducted.
  • Oral heparin utilized Emisphere's proprietary carrier molecule P-414 (SNAC).
  • Studies involved patients undergoing hip replacement surgery, comparing oral heparin to injectable forms.

Related Experiment Videos

Main Results:

  • Phase I trials demonstrated successful absorption and pharmacokinetic effects.
  • Phase II and III trials showed oral heparin was comparable in safety and efficacy to subcutaneous heparin.
  • Positive preliminary and final results supported the oral formulation's potential.

Conclusions:

  • Oral heparin formulation using P-414 is a viable alternative for DVT prevention.
  • The formulation shows comparable safety and efficacy to injectable heparin.
  • Further development and partnerships are planned for broader indications.